Evidence map›Paper›PMID 25899799›Full record

ArticleAAPS PharmSciTech2015

Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery.

Swapnil A Malekar, Ashish L Sarode, Alvin C Bach, Arijit Bose, Geoffrey Bothun, David R Worthen

Open access · bronzeAbstract read
In one paragraph

Article in AAPS PharmSciTech, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. An update on selective estrogen receptor modulator: repurposing and formulations.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Swapnil A MalekarDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, 02881, USA.
Ashish L SarodeDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, 02881, USA.
Alvin C BachDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, 02881, USA.
Arijit BoseDepartment of Chemical Engineering, College of Engineering, University of Rhode Island, 495M Pharmacy Building, 7 Greenhouse Drive, Kingston, Rhode Island, 02881, USA.
Geoffrey BothunDepartment of Chemical Engineering, College of Engineering, University of Rhode Island, 495M Pharmacy Building, 7 Greenhouse Drive, Kingston, Rhode Island, 02881, USA.
David R WorthenDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, 02881, USA. drworthen@uri.edu.
University of Rhode Island · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequency-induced, hydrophobic magnetic nanoparticle-dependent triggering mechanism for drug release. Both drugs were successfully incorporated into liposomes by lipid film hydration, although combination drug loading compromised liposome stability. Liposome stability was improved by reducing the drug load and by including Pluronics® (PL) in the formulations. DOX did not appear to interact with the phospholipid membranes comprising the liposomes, and its release was maximized in the presence of radio frequency (RF) heating. In contrast, differential scanning calorimetry (DSC) and phosphorus-31 nuclear magnetic resonance ((31)P-NMR) analysis revealed that RAL developed strong interactions with the phospholipid membranes, most notably with lipid phosphate head groups, resulting in significant changes in membrane thermodynamics. Likewise, RAL release from liposomes was minimal, even in the presence of RF heating. These studies may offer useful insights into the design and optimization of multidrug containing liposomes. The effects of RAL on liposome characteristics and drug release performance underscore the importance of appropriate physical-chemical analysis in order to identify and characterize drug-lipid interactions that may profoundly affect liposome properties and performance early in the formulation development process.

Indexed as

Chemistry, PharmaceuticalDelayed-Action PreparationsDoxorubicinDrug CombinationsDrug Delivery SystemsDrug StabilityHydrophobic and Hydrophilic InteractionsLiposomesNanoparticlesPhospholipidsPoloxamerDelayed-Action PreparationsDoxorubicinDrug CombinationsLiposomesPhospholipidsPoloxamercontrolled releasedrug combinationliposomesnanoparticles

Identifiers

PMID25899799
PMCPMC4666254
OpenAlexW2003837630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.